Esophageal Squamous Cell Carcinoma

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
EMA (2)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Ipilimumab, Nivolumab
EMA (1)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Nivolumab
EMA (1)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Tislelizumab
EMA (1)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Capecitabine, Cisplatin, Tislelizumab
EMA (1)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Fluorouracil, Oxaliplatin, Tislelizumab
EMA (1)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Capecitabine, Oxaliplatin, Tislelizumab
EMA (1)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab
EMA (1)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Oxaliplatin, Paclitaxel, Tislelizumab
FDA (1)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Tislelizumab
FDA (1)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Capecitabine, Cisplatin, Tislelizumab
FDA (1)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Fluorouracil, Oxaliplatin, Tislelizumab
FDA (1)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Capecitabine, Oxaliplatin, Tislelizumab
FDA (1)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab
FDA (1)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Oxaliplatin, Paclitaxel, Tislelizumab
FDA (1)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Tislelizumab
FDA (1)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Capecitabine, Cisplatin, Tislelizumab
FDA (1)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Fluorouracil, Oxaliplatin, Tislelizumab
FDA (1)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Capecitabine, Oxaliplatin, Tislelizumab
FDA (1)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab
FDA (1)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Oxaliplatin, Paclitaxel, Tislelizumab